ML-T7

ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab. ML-T7 can be used for tumor immunotherapy research^[1].

ML-T7(10 μM, 0-6 days) enhances TCR/STAT5 signaling and promotes CD8+ cell antitumor activity through Tim-3^[1].
ML-T7(10 μM, 24 h) promotes DC maturation and function through Tim-3 and Tim-4, enhances DC antigen-presenting ability^[1].
ML-T7(10 μM, 24 h) enhances CTL activation and cytokine production, decreases apoptosis of CTLs^[1].
ML-T7(10 μM, 48 h) significantly enhances the production of IFN-γ, TNF-α, CD107a, and granzyme B in human NK cell line NK92 cells^[1].

ML-T7 (10-50 mg/kg; Intraperitoneal injection; every 2 days, 10 times) inhibits the growth of tumor and prolongs survival of HCC mice, without adverse effects on mice body weight^[1].
ML-T7 (20 mg/kg; Intraperitoneal injection; every 2 days, 10 times) synergizes with Nivolumab to improve the antitumor efficacy of Nivolumab antibodies, and effectively improves HCC mice survival^[1].
ML-T7 (50 mg/kg, Intraperitoneal injection; every 2 days for 3 weeks)shows a good safety profile in mice^[1].

References:
[1]. Ma S, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023 Nov 15;15(722):eadg6752.

ML-T7 是一种有效的 Tim-3 抑制剂。ML-T7 阻断 Tim-3 与 PtdSer 和 CEACAM1 的相互作用。ML-T7 不仅增强 CTLs 和 CAR T 细胞过继转移治疗的抗肿瘤活性，而且还增强 T 细胞的效应功能。ML-T7 促进 NK 细胞对肿瘤细胞的杀伤活性和 DC 抗原呈递能力。ML-T7 单独使用或与 Nivolumab 联合使用可在临床前肿瘤模型中直接发挥抗肿瘤功效。ML-T7 可用于肿瘤免疫治疗研究。

ML-T7(10 μM, 0-6 days) 通过Tim-3增强TCR/STAT5信号通路，促进CD8+细胞抗肿瘤活性^[1]。
ML-T7(10 μM, 24 h) 可通过Tim-3和Tim-4促进DC的成熟和功能,增强DC抗原呈递能力^[1]。
ML-T7(10 μM, 24 h) 增强CTL激活和细胞因子产生，减少CTLs的凋亡^[1]。
ML-T7(10 μM, 48 h) 可显著增强人NK 细胞系NK92细胞中IFN-γ、TNF-α、CD107a 和granzyme B的产生^[1]。

ML-T7 (10-50 mg/kg; 腹腔注射; every 2 days, 10 times) 抑制肿瘤生长并延长小鼠的生存期，对小鼠体重无不良影响^[1]。
ML-T7 (20 mg/kg; 腹腔注射; every 2 days, 10 times)和 Nivolumab 联合治疗可提升 Nivolumab 抗体的抗肿瘤效果，同时可有效提高HCC小鼠存活率^[1]。
ML-T7 (50 mg/kg, 腹腔注射; every 2 days for 3 weeks)在小鼠中表现出良好的安全性^[1]。